Skip to main content
Erschienen in: Medizinische Klinik - Intensivmedizin und Notfallmedizin 6/2021

01.08.2021 | Tachykarde Herzrhythmusstörungen | CME

Medikamentöse Therapie des Kreislaufschocks

verfasst von: Prof. Dr. med. Reimer Riessen, Rubi Stephani Hellwege, M.Sc.

Erschienen in: Medizinische Klinik - Intensivmedizin und Notfallmedizin | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Ein Kreislaufschock erfordert neben einer kausalen Therapie der wichtigsten pathologischen Ursachen eine supportive medikamentöse Behandlung, die durch ein hämodynamisches Monitoring gesteuert wird. Basierend auf der individuellen Einschätzung des Volumenstatus, des Perfusionsstatus und des kardialen Status sollten folgende Therapieziele erreicht werden: 1. Normalisierung des intra- und extravasalen Flüssigkeitsvolumens; 2. Sicherung eines ausreichenden Perfusionsdrucks und einer ausreichenden Organperfusion; 3. Optimierung der kardialen Funktion inklusive Schutz eines ischämischen oder erschöpften Myokards vor Überlastung. Die wichtigsten therapeutischen Substanzen sind balancierte Elektrolytlösungen und der Vasopressor Noradrenalin. Für die Gabe alternativer Medikamente gibt es nur wenig wissenschaftliche Evidenz, sodass ihr Einsatz gut begründet und ihr Effekt im Rahmen des Monitorings engmaschig überwacht und bewertet werden sollte.
Literatur
1.
Zurück zum Zitat Schumann J, Henrich EC, Strobl H et al (2018) Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev 1:Cd9669PubMed Schumann J, Henrich EC, Strobl H et al (2018) Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev 1:Cd9669PubMed
2.
Zurück zum Zitat Lat I, Coopersmith CM, De Backer D et al (2021) The surviving sepsis campaign: fluid resuscitation and vasopressor therapy research priorities in adult patients. Crit Care Med 49:623–635PubMedPubMedCentralCrossRef Lat I, Coopersmith CM, De Backer D et al (2021) The surviving sepsis campaign: fluid resuscitation and vasopressor therapy research priorities in adult patients. Crit Care Med 49:623–635PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Marik PE, Weinmann M (2019) Optimizing fluid therapy in shock. Curr Opin Crit Care 25:246–251PubMedCrossRef Marik PE, Weinmann M (2019) Optimizing fluid therapy in shock. Curr Opin Crit Care 25:246–251PubMedCrossRef
4.
Zurück zum Zitat Dünser MW, Takala J, Brunauer A et al (2013) Re-thinking resuscitation: leaving blood pressure cosmetics behind and moving forward to permissive hypotension and a tissue perfusion-based approach. Crit Care 17:326PubMedPubMedCentralCrossRef Dünser MW, Takala J, Brunauer A et al (2013) Re-thinking resuscitation: leaving blood pressure cosmetics behind and moving forward to permissive hypotension and a tissue perfusion-based approach. Crit Care 17:326PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Panwar R, Tarvade S, Lanyon N et al (2020) Relative hypotension and adverse kidney-related outcomes among critically ill patients with shock. A multicenter, prospective cohort study. Am J Respir Crit Care Med 202:1407–1418PubMedCrossRef Panwar R, Tarvade S, Lanyon N et al (2020) Relative hypotension and adverse kidney-related outcomes among critically ill patients with shock. A multicenter, prospective cohort study. Am J Respir Crit Care Med 202:1407–1418PubMedCrossRef
7.
Zurück zum Zitat Teboul J‑L, Saugel B, Cecconi M et al (2016) Less invasive hemodynamic monitoring in critically ill patients. Intensive Care Med 42:1350–1359PubMedCrossRef Teboul J‑L, Saugel B, Cecconi M et al (2016) Less invasive hemodynamic monitoring in critically ill patients. Intensive Care Med 42:1350–1359PubMedCrossRef
8.
Zurück zum Zitat Repessé X, Charron C, Vieillard-Baron A (2015) Acute cor pulmonale in ARDS: rationale for protecting the right ventricle. Chest 147:259–265PubMedCrossRef Repessé X, Charron C, Vieillard-Baron A (2015) Acute cor pulmonale in ARDS: rationale for protecting the right ventricle. Chest 147:259–265PubMedCrossRef
9.
Zurück zum Zitat Joffre J, Hellman J, Ince C et al (2020) Endothelial responses in sepsis. Am J Respir Crit Care Med 202:361–370PubMedCrossRef Joffre J, Hellman J, Ince C et al (2020) Endothelial responses in sepsis. Am J Respir Crit Care Med 202:361–370PubMedCrossRef
10.
Zurück zum Zitat Silversides JA, Major E, Ferguson AJ et al (2017) Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis. Intensive Care Med 43:155–170PubMedCrossRef Silversides JA, Major E, Ferguson AJ et al (2017) Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis. Intensive Care Med 43:155–170PubMedCrossRef
11.
Zurück zum Zitat Janssens U (2016) Hämodynamisches Monitoring kritisch Kranker. Med Klin Intensivmed Notfmed 111:619–629CrossRef Janssens U (2016) Hämodynamisches Monitoring kritisch Kranker. Med Klin Intensivmed Notfmed 111:619–629CrossRef
15.
Zurück zum Zitat Spahn DR, Bouillon B, Cerny V et al (2019) The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care 23:98PubMedPubMedCentralCrossRef Spahn DR, Bouillon B, Cerny V et al (2019) The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care 23:98PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Wiedermann CJ, Joannidis M (2014) Accumulation of hydroxyethyl starch in human and animal tissues: a systematic review. Intensive Care Med 40:160–170PubMedCrossRef Wiedermann CJ, Joannidis M (2014) Accumulation of hydroxyethyl starch in human and animal tissues: a systematic review. Intensive Care Med 40:160–170PubMedCrossRef
17.
Zurück zum Zitat Hernández G, Teboul J‑L, Bakker J (2019) Norepinephrine in septic shock. Intensive Care Med 45:687–689PubMedCrossRef Hernández G, Teboul J‑L, Bakker J (2019) Norepinephrine in septic shock. Intensive Care Med 45:687–689PubMedCrossRef
18.
Zurück zum Zitat Li Y, Li H, Zhang D (2020) Timing of norepinephrine initiation in patients with septic shock: a systematic review and meta-analysis. Crit Care 24:488PubMedPubMedCentralCrossRef Li Y, Li H, Zhang D (2020) Timing of norepinephrine initiation in patients with septic shock: a systematic review and meta-analysis. Crit Care 24:488PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Roberts RJ, Miano TA, Hammond DA et al (2020) Evaluation of vasopressor exposure and mortality in patients with septic shock. Crit Care Med 48:1445–1453PubMedCrossRef Roberts RJ, Miano TA, Hammond DA et al (2020) Evaluation of vasopressor exposure and mortality in patients with septic shock. Crit Care Med 48:1445–1453PubMedCrossRef
20.
Zurück zum Zitat Schellenberg M, Cobb JP (2020) Fluid resuscitation and vasopressors in septic shock: the importance of filling the tank while squeezing the pipes. Crit Care Med 48:1533–1535PubMedCrossRef Schellenberg M, Cobb JP (2020) Fluid resuscitation and vasopressors in septic shock: the importance of filling the tank while squeezing the pipes. Crit Care Med 48:1533–1535PubMedCrossRef
21.
Zurück zum Zitat Hoste EA, Maitland K, Brudney CS et al (2014) Four phases of intravenous fluid therapy: a conceptual model. Br J Anaesth 113:740–747PubMedCrossRef Hoste EA, Maitland K, Brudney CS et al (2014) Four phases of intravenous fluid therapy: a conceptual model. Br J Anaesth 113:740–747PubMedCrossRef
22.
Zurück zum Zitat Russell JA (2019) Vasopressor therapy in critically ill patients with shock. Intensive Care Med 45:1503–1517PubMedCrossRef Russell JA (2019) Vasopressor therapy in critically ill patients with shock. Intensive Care Med 45:1503–1517PubMedCrossRef
23.
Zurück zum Zitat Werdan K, Boeken U, Briegel MJ et al (2020) Kurzversion der 2. Auflage der deutsch-österreichischen S3-Leitlinie „Infarkt-bedingter Kardiogener Schock – Diagnose, Monitoring und Therapie“. Kardiologe 14:364–395CrossRef Werdan K, Boeken U, Briegel MJ et al (2020) Kurzversion der 2. Auflage der deutsch-österreichischen S3-Leitlinie „Infarkt-bedingter Kardiogener Schock – Diagnose, Monitoring und Therapie“. Kardiologe 14:364–395CrossRef
24.
Zurück zum Zitat Zideman DA, Singletary EM, Borra V et al (2021) European resuscitation council guidelines 2021: first aid. Resuscitation 161:270–290PubMedCrossRef Zideman DA, Singletary EM, Borra V et al (2021) European resuscitation council guidelines 2021: first aid. Resuscitation 161:270–290PubMedCrossRef
26.
Zurück zum Zitat Riessen R, Tschritter O, Janssens U et al (2016) Katecholamine: Pro und Kontra. Med Klin Intensivmed Notfmed 111:37–46CrossRef Riessen R, Tschritter O, Janssens U et al (2016) Katecholamine: Pro und Kontra. Med Klin Intensivmed Notfmed 111:37–46CrossRef
27.
Zurück zum Zitat Nagy L, Pollesello P, Papp Z (2014) Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus. J Cardiovasc Pharmacol 64:199–208PubMedPubMedCentralCrossRef Nagy L, Pollesello P, Papp Z (2014) Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus. J Cardiovasc Pharmacol 64:199–208PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Petersen JW, Felker GM (2008) Inotropes in the management of acute heart failure. Crit Care Med 36:S106–111PubMedCrossRef Petersen JW, Felker GM (2008) Inotropes in the management of acute heart failure. Crit Care Med 36:S106–111PubMedCrossRef
29.
Zurück zum Zitat Huizar JF, Ellenbogen KA, Tan AY et al (2019) Arrhythmia-induced cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73:2328–2344PubMedPubMedCentralCrossRef Huizar JF, Ellenbogen KA, Tan AY et al (2019) Arrhythmia-induced cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73:2328–2344PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Pelliccia F, Kaski JC, Crea F et al (2017) Pathophysiology of Takotsubo syndrome. Circulation 135:2426–2441PubMedCrossRef Pelliccia F, Kaski JC, Crea F et al (2017) Pathophysiology of Takotsubo syndrome. Circulation 135:2426–2441PubMedCrossRef
31.
Zurück zum Zitat Belletti A, Castro ML, Silvetti S et al (2015) The effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. Br J Anaesth 115:656–675PubMedCrossRef Belletti A, Castro ML, Silvetti S et al (2015) The effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials. Br J Anaesth 115:656–675PubMedCrossRef
32.
Zurück zum Zitat Moller MH, Granholm A, Junttila E et al (2018) Scandinavian SSAI clinical practice guideline on choice of inotropic agent for patients with acute circulatory failure. Acta Anaesthesiol Scand 62:420–450PubMedPubMedCentralCrossRef Moller MH, Granholm A, Junttila E et al (2018) Scandinavian SSAI clinical practice guideline on choice of inotropic agent for patients with acute circulatory failure. Acta Anaesthesiol Scand 62:420–450PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Léopold V, Gayat E, Pirracchio R et al (2018) Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Med 44:847–856PubMedCrossRef Léopold V, Gayat E, Pirracchio R et al (2018) Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Med 44:847–856PubMedCrossRef
34.
Zurück zum Zitat Levy B, Perez P, Perny J et al (2011) Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med 39:450–455PubMedCrossRef Levy B, Perez P, Perny J et al (2011) Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med 39:450–455PubMedCrossRef
35.
Zurück zum Zitat Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 37:2129–2200PubMedCrossRef Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 37:2129–2200PubMedCrossRef
36.
Zurück zum Zitat Annane D, Ouanes-Besbes L, De Backer D et al (2018) A global perspective on vasoactive agents in shock. Intensive Care Med 44:833–846PubMedCrossRef Annane D, Ouanes-Besbes L, De Backer D et al (2018) A global perspective on vasoactive agents in shock. Intensive Care Med 44:833–846PubMedCrossRef
38.
Zurück zum Zitat van Diepen S, Katz JN, Albert NM et al (2017) Contemporary management of cardiogenic shock: a scientific statement from the American heart association. Circulation 136:e232–e268PubMed van Diepen S, Katz JN, Albert NM et al (2017) Contemporary management of cardiogenic shock: a scientific statement from the American heart association. Circulation 136:e232–e268PubMed
39.
Zurück zum Zitat Papp Z, Agostoni P, Alvarez J et al (2020) Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use. J Cardiovasc Pharmacol 76:4–22PubMedPubMedCentral Papp Z, Agostoni P, Alvarez J et al (2020) Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use. J Cardiovasc Pharmacol 76:4–22PubMedPubMedCentral
40.
Zurück zum Zitat Fuhrmann JT, Schmeisser A, Schulze MR et al (2008) Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 36:2257–2266PubMedCrossRef Fuhrmann JT, Schmeisser A, Schulze MR et al (2008) Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 36:2257–2266PubMedCrossRef
41.
Zurück zum Zitat Herpain A, Bouchez S, Girardis M et al (2019) Use of levosimendan in intensive care unit settings: an opinion paper. J Cardiovasc Pharmacol 73:3–14PubMedCrossRef Herpain A, Bouchez S, Girardis M et al (2019) Use of levosimendan in intensive care unit settings: an opinion paper. J Cardiovasc Pharmacol 73:3–14PubMedCrossRef
42.
Zurück zum Zitat Gordon AC, Perkins GD, Singer M et al (2016) Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med 375:1638–1648PubMedCrossRef Gordon AC, Perkins GD, Singer M et al (2016) Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med 375:1638–1648PubMedCrossRef
43.
Zurück zum Zitat Donnino MW, Salciccioli JD, Howell MD et al (2014) Time to administration of epinephrine and outcome after in-hospital cardiac arrest with non-shockable rhythms: retrospective analysis of large in-hospital data registry. BMJ 348:g3028PubMedPubMedCentralCrossRef Donnino MW, Salciccioli JD, Howell MD et al (2014) Time to administration of epinephrine and outcome after in-hospital cardiac arrest with non-shockable rhythms: retrospective analysis of large in-hospital data registry. BMJ 348:g3028PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Sander O, Welters ID, Foëx P et al (2005) Impact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with a high risk of cardiac complications. Crit Care Med 33:81–88 (discussion 241–242)PubMedCrossRef Sander O, Welters ID, Foëx P et al (2005) Impact of prolonged elevated heart rate on incidence of major cardiac events in critically ill patients with a high risk of cardiac complications. Crit Care Med 33:81–88 (discussion 241–242)PubMedCrossRef
45.
Zurück zum Zitat Kakihana Y, Nishida O, Taniguchi T et al (2020) Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med 8:863–872PubMedCrossRef Kakihana Y, Nishida O, Taniguchi T et al (2020) Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med 8:863–872PubMedCrossRef
46.
Zurück zum Zitat Lee YR, Seth MS, Soney D et al (2019) Benefits of beta-blockade in sepsis and septic shock: a systematic review. Clin Drug Investig 39:429–440PubMedCrossRef Lee YR, Seth MS, Soney D et al (2019) Benefits of beta-blockade in sepsis and septic shock: a systematic review. Clin Drug Investig 39:429–440PubMedCrossRef
47.
Zurück zum Zitat Morelli A, Ertmer C, Westphal M et al (2013) Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 310:1683–1691PubMedCrossRef Morelli A, Ertmer C, Westphal M et al (2013) Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 310:1683–1691PubMedCrossRef
Metadaten
Titel
Medikamentöse Therapie des Kreislaufschocks
verfasst von
Prof. Dr. med. Reimer Riessen
Rubi Stephani Hellwege, M.Sc.
Publikationsdatum
01.08.2021
Verlag
Springer Medizin
Erschienen in
Medizinische Klinik - Intensivmedizin und Notfallmedizin / Ausgabe 6/2021
Print ISSN: 2193-6218
Elektronische ISSN: 2193-6226
DOI
https://doi.org/10.1007/s00063-021-00838-9

Weitere Artikel der Ausgabe 6/2021

Medizinische Klinik - Intensivmedizin und Notfallmedizin 6/2021 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.